- Home
- UPST vs GH Comparison
UPST vs GH Comparison
Compare UPST & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UPST
- GH
- Stock Information
- Founded
- UPST 2012
- GH 2011
- Country
- UPST United States
- GH United States
- Employees
- UPST N/A
- GH N/A
- Industry
- UPST Finance: Consumer Services
- GH Medical Specialities
- Sector
- UPST Finance
- GH Health Care
- Exchange
- UPST Nasdaq
- GH Nasdaq
- Market Cap
- UPST 5.5B
- GH 4.9B
- IPO Year
- UPST 2020
- GH 2018
- Fundamental
- Price
- UPST $67.17
- GH $55.40
- Analyst Decision
- UPST Buy
- GH Strong Buy
- Analyst Count
- UPST 15
- GH 17
- Target Price
- UPST $74.04
- GH $58.24
- AVG Volume (30 Days)
- UPST 6.5M
- GH 2.3M
- Earning Date
- UPST 11-06-2025
- GH 11-05-2025
- Dividend Yield
- UPST N/A
- GH N/A
- EPS Growth
- UPST N/A
- GH N/A
- EPS
- UPST N/A
- GH N/A
- Revenue
- UPST $884,807,000.00
- GH $828,849,000.00
- Revenue This Year
- UPST $59.24
- GH $28.07
- Revenue Next Year
- UPST $26.99
- GH $21.61
- P/E Ratio
- UPST N/A
- GH N/A
- Revenue Growth
- UPST 53.62
- GH 28.74
- 52 Week Low
- UPST $31.40
- GH $20.14
- 52 Week High
- UPST $96.43
- GH $68.00
- Technical
- Relative Strength Index (RSI)
- UPST 49.16
- GH 50.62
- Support Level
- UPST $61.15
- GH N/A
- Resistance Level
- UPST $69.75
- GH $61.95
- Average True Range (ATR)
- UPST 3.81
- GH 2.30
- MACD
- UPST 0.01
- GH -3.45
- Stochastic Oscillator
- UPST 38.68
- GH 81.47
About UPST Upstart Holdings Inc.
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. Upstart's platform includes personal loans, automotive retail and refinance loans, home equity lines of credit, and small-dollar loans.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.